Literature DB >> 24892479

Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*.

Dennis W Simon1, Rajesh Aneja, Joseph A Carcillo, E Scott Halstead.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24892479      PMCID： PMC5091288          DOI： 10.1097/PCC.0000000000000098

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN： 1529-7535            Impact factor:   3.624


× No keyword cloud information.
  19 in total

1.  Successful treatment of non-familial haemophagocytic lymphohistiocytosis with interferon and gammaglobulin.

Authors:  E J Estlin; R D Palmer; K P Windebank; M F Lowry; A D Pearson
Journal:  Arch Dis Child       Date:  1996-11       Impact factor: 3.791

2.  Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.

Authors:  N K Loh; M Lucas; S Fernandez; D Prentice
Journal:  Intern Med J       Date:  2012-12       Impact factor: 2.048

3.  Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

Authors:  Edward M Behrens; Scott W Canna; Katharine Slade; Sheila Rao; Portia A Kreiger; Michele Paessler; Taku Kambayashi; Gary A Koretzky
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

4.  A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells.

Authors:  Hironori Tsujimoto; Satoshi Ono; Atsushi Matsumoto; Toshinobu Kawabata; Manabu Kinoshita; Takashi Majima; Shuichi Hiraki; Shuhji Seki; Lyle L Moldawer; Hidetaka Mochizuki
Journal:  J Hepatol       Date:  2006-09-22       Impact factor: 25.083

5.  A case of macrophage activation syndrome successfully treated with anakinra.

Authors:  Alison Kelly; Athimalaipet V Ramanan
Journal:  Nat Clin Pract Rheumatol       Date:  2008-09-30

6.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

7.  Trends in the epidemiology of pediatric severe sepsis*.

Authors:  Mary E Hartman; Walter T Linde-Zwirble; Derek C Angus; R Scott Watson
Journal:  Pediatr Crit Care Med       Date:  2013-09       Impact factor: 3.624

Review 8.  Familial hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Eur J Pediatr       Date:  1983 Jun-Jul       Impact factor: 3.183

9.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

Review 10.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775
View more
  10 in total

1.  Editorial: 21st Century Storm Chasers: Defining Macrophage Activation Syndrome.

Authors:  Scott W Canna; Peter A Nigrovic
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 2.  Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.

Authors:  Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 3.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 4.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

5.  How We Manage Hyperferritinemic Sepsis-Related Multiple Organ Dysfunction Syndrome/Macrophage Activation Syndrome/Secondary Hemophagocytic Lymphohistiocytosis Histiocytosis.

Authors:  Joseph A Carcillo; Dennis W Simon; Bradley S Podd
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

6.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Authors:  Bita Shakoory; Joseph A Carcillo; W Winn Chatham; Richard L Amdur; Huaqing Zhao; Charles A Dinarello; Randall Q Cron; Steven M Opal
Journal:  Crit Care Med       Date:  2016-02       Impact factor: 7.598

Review 7.  Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis.

Authors:  Rebecca A Marsh
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

Review 8.  Treatment algorithm for COVID-19: a multidisciplinary point of view.

Authors:  Felice Galluccio; Tolga Ergonenc; Alvaro Garcia Martos; Abdallah El-Sayed Allam; Maria Pérez-Herrero; Ricardo Aguilar; Giacomo Emmi; Michele Spinicci; Ignacio Terrancle Juan; Mario Fajardo-Pérez
Journal:  Clin Rheumatol       Date:  2020-05-29       Impact factor: 2.980

9.  Systemic autoimmune abnormalities complicated by cytomegalovirus-induced hemophagocytic lymphohistiocytosis: A case report.

Authors:  Shu-Xian Miao; Zhi-Qi Wu; Hua-Guo Xu
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

Review 10.  The off-label use of anakinra in pediatric systemic autoinflammatory diseases.

Authors:  Valerio Maniscalco; Sarah Abu-Rumeileh; Maria Vincenza Mastrolia; Edoardo Marrani; Ilaria Maccora; Ilaria Pagnini; Gabriele Simonini
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-16       Impact factor: 5.346
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.